Rimonext Pomegranate Emulsion
Rimonext Pomegranate Emulsion is the result of over ten years intensive research on anticancer properties of the pomegranate fruit, begun at the Technion—Israel Institute of Technology in 1999. Initial work the year earlier proved pomegranate juice, after controlled fermentation, to possess one of the highest antioxidant activities ever discovered in nature (1). This juice, but especially polyphenolic compounds in the seed oil, also proved to be potent inhibitors of two key enzymes (proteins that catalyze biochemical reactions) responsible for inflammation (1).
The work begun in 1999 initially focused on estrogenic activity of the seed oil, previously reported from animal studies in 1964. The 1999 in vitro studies confirmed mild estrogenic activity of the seed oil, but more importantly, proved that the juice possessed anti-estrogenic action. This finding was particularly relevant since excess estrogenic activity was known to stimulate certain types of breast cancer. Further work showed fermented pomegranate juice (and only weakly so, fresh pomegranate juice), a potent inhibitor of enzymes catalyzing estrogen production in the body. Fermented pomegranate juice extract thus had an action similar to that of a popular class of conventional drugs used to treat breast cancer, i.e., by suppressing enzyme aromatase (2)! Indeed, ongoing investigations showed fermented pomegranate juice extracts to powerfully slow proliferation of both estrogen responsive and estrogen non-responsive types of breast cancer cells, while pomegranate seed oil in very small doses decreased invasion of breast cancer cells (invasiveness leads to metastasis) and in larger doses, promoted apoptosis (genetically-triggered cancer cell self-destruction) (2).
Angiogenesis,the production of new blood vessels from existing blood vessels, is required by cancers to metastasize, to spread to distant sites in the body. In human breast cancer, pomegranate fermented juice extract (but not fresh pomegranate juice) and pomegranate seed oil each potently suppressed angiogenesis at both the cellular and biochemical levels (3).
Differentiation is the process whereby cancer cells that have lost their ability to function as normal cells in the body regain normal function. Differentiation represents an attractive means of cancer treatment not relying on direct killing of cells. In human leukemia cells, pomegranate fermented juice extract (and only very weakly so, fresh pomegranate juice extract) and also pomegranate peel extract proved potent promoters of cancer cell differentiation (4).
Cancers begin as single cells that are transformed, and these cells multiply to produce clones that become the clinical cancers. The beginning of the cancer is caused by initiation, and stimulation of the ongoing development of cancer is called promotion. Pomegranate fermented juice extract, pomegranate peel extract and pomegranate seed oil prevent cancer initiation and promotion in animal models of breast cancer (5) and skin cancer (6).
Oncogenes are genes that when turned on, lead to a cascade of biochemical events that initiate and promote cancer. Pomegranate fermented juice extract and pomegranate seed oil prevent specific oncogenes from being turned on, and also stimulate specific oncogenes to turn off, stopping cancer from starting and developing at the level of the gene (7). These extracts also reduced cancerous tumor volume in mice by 75% (7).
Synergy occurs when two or more different medicines are combined to produce an effect greater than the sum of their individual effects. When pomegranate fermented juice extract was combined with even a tiny, sub-therapeutic amount of pomegranate seed oil, synergistic suppression of cancer cell proliferation was observed (8). Synergistic suppression of proliferation also occurred when pomegranate fermented juice extract was combined with a tiny, sub-therapeutic amount of pomegranate peel extract (8). When equal amounts of pomegranate fermented juice extract, pomegranate peel extract and pomegranate seed oil were combined, the result was an astonishing synergistic suppression of cancer cell invasion and cancer cell inflammation approaching 99% (8) (Figure 1). When pure chemicals isolated from pomegranate fermented juice extract, pomegranate peel extract and pomegranate seed oil were combined in equal amounts, a similar, statistically significant suppression of cancer cell invasion occurred (9).
Inflammation is a normal response of the body and its systems to stress. For example, trauma or infection causes leakiness of blood vessels facilitating white blood cells to flow to and repair the injured or infected area, showing the cardinal signs of inflammation: redness, swelling, heat and pain, but ultimately benefiting the organism and enabling healing. Inflammation may also be counterproductive, leading to initiation, promotion and metastasis of cancers. Pomegranate peel extract powerfully inhibits a key enzyme that leads to leakiness of blood vessels and inflammation (10). Pomegranate fermented juice extract reduces inflammation in individual cancer cells by suppressing expression of a particular inflammatory protein factor, “NF-kappa-B” and also reduces the motility of cancer cells (11). The reduction of inflammation at the cellular level is a key mechanism in the multiple anticancer effects of pomegranate fractions (12).
Estrogenic effects may help promote inflammation and many different types of cancer. Pomegranate fruit, including its peels (13) and seed oil (14), is rich in mild, safe estrogens that “compete” with strong estrogens produced by the body to “selectively modulate” estrogen receptors to regulate and maintain endocrine (hormonal) health. Selective estrogen receptor modulation is another powerful mechanism by which pomegranate fruit fractions help control both cancer and inflammation.
Inflammation is a key causative factor in many diseases other than cancer. Chronic inflammation is closely related to chronic insulin resistance associated with metabolic syndrome, which can lead to cancer, obesity, cardiovascular disease and diabetes. Pomegranate fractions are beneficial for all of these problems; their value in diabetes (15) and inflammatory diseases and general health maintenance in men and women (16) has been reviewed.
Rimonext Pomegranate Emulsion was first produced in Israel in 2006 for an animal trial at the University of Michigan, USA. Two groups of 30 female mice each with the HER2/NEU genetic defect (all eventually get breast cancer) received either Rimonext Pomegranate Emulsion or placebo emulsion. By 40 weeks, 25% of the mice receiving placebo emulsion had developed breast cancer, but mice receiving the Rimonext Pomegranate Emulsion were still 100% cancer-free (17). In a larger second trial at Northeastern Ohio University School of Medicine and Pharmacy (USA), rats received a chemical causing breast cancer and were then treated daily with either placebo emulsion or Pomegranate Emulsion. The animals receiving Pomegranate Emulsion showed a strong, statistically significant reduction in cancer occurrence.
Since 2006, Rimonext Pomegranate Emulsion has been used by almost 100 patients with cancers of the breast, prostate, lung, pancreas, thyroid and liver as well as leukemias and, lymphomas, all supervised by physicians. In almost all cases Rimonext Pomegranate Emulsion was well tolerated, and in many, major improvements in general health, well-being and cancer status (measured by biochemical markers, imaging and physical examination) were reported. Other patients with diabetes, Crohn’s disease and obesity also reported substantial benefits ranging from reduction in blood sugar, relief of diarrhea and normalization of body weight.
Rimonext Pomegranate Emulsion was approved in December 2008 by the Israel Ministry of Health as a safe nutritional supplement for oral use. The recommended dosage is 1 teaspoon (5 ml.) one to three times daily, alone or dissolved in fruit juice, water or tea. It may also be incorporated into foods. Rimonext Pomegranate Emulsion is unsweetened and contains no sugar or alcohol. All pomegranates used in its preparation are grown in Israel under strict organic and kosher supervision.
Rimonext Pomegranate Emulsion may also be incorporated into cosmeceutical products permitting water. Examples are creams and lotions, soaps, shampoos and conditioners, including those used to prevent or treat skin or hair damage from the sun.
Additional study and development of Rimonext Pomegranate Emulsion is ongoing. Rimonext Pomegranate Emulsion’s therapeutic power derives not from a single compound (18) but from the synergistic interactions inherent in its complexity (19). More detailed scientific information about Rimonext Pomegranate Emulsion and its components can be found from the cited publications, including a 400 page doctoral thesis (20), and websites: www.Rimonext.com and www.punisyn.com. The inventor of Pomegranate Emulsion is Ephraim Philip Lansky, who has researched medicinal benefits of pomegranate fruit since 1992. Dr. Lansky holds an M.D. from the University of Pennsylvania School of Medicine (USA), a Ph.D. in pharmacognosy (pharmacology of crude drugs) from Leiden University (The Netherlands), an M.B.A. from Bradford University (UK) and a B.A. in psychology / biology from New College in Sarasota, Florida (USA). He is the author of five patents relating to pomegranate health products issued in the USA, Israel, Australia and South Africa, and a pending patent in Japan. His latest book (co-authored with Helena Maaria Paavilainen) is Fig: The Genus Ficus, published by CRC Press (a Taylor and Francis imprint) in the summer of 2010. Dr. Lansky can be reached for questions, comments and ordering the Rimonext Pomegranate Emulsion for research purposes though the email: [email protected], post: POB 9945, Haifa, Israel, or telephone +972-77-300-1612 (in Israel, 077-300-1612). Checks not accepted. Payment by cash or wire transfer only.